BRPI1016109A2 - "composto, composição farmacêutica, e, processo para preparar um composto" - Google Patents
"composto, composição farmacêutica, e, processo para preparar um composto"Info
- Publication number
- BRPI1016109A2 BRPI1016109A2 BRPI1016109A BRPI1016109A BRPI1016109A2 BR PI1016109 A2 BRPI1016109 A2 BR PI1016109A2 BR PI1016109 A BRPI1016109 A BR PI1016109A BR PI1016109 A BRPI1016109 A BR PI1016109A BR PI1016109 A2 BRPI1016109 A2 BR PI1016109A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- preparing
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21853909P | 2009-06-19 | 2009-06-19 | |
| PCT/GB2010/051003 WO2010146395A1 (en) | 2009-06-19 | 2010-06-17 | Pyrazine carboxamides as inhibitors of dgat1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1016109A2 true BRPI1016109A2 (pt) | 2016-05-17 |
Family
ID=42357808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1016109A BRPI1016109A2 (pt) | 2009-06-19 | 2010-06-17 | "composto, composição farmacêutica, e, processo para preparar um composto" |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8188092B2 (pt) |
| EP (1) | EP2443096A1 (pt) |
| JP (1) | JP2012530122A (pt) |
| KR (1) | KR20120037939A (pt) |
| CN (1) | CN102498103A (pt) |
| AR (1) | AR077140A1 (pt) |
| AU (1) | AU2010261499A1 (pt) |
| BR (1) | BRPI1016109A2 (pt) |
| CA (1) | CA2764013A1 (pt) |
| MX (1) | MX2011014018A (pt) |
| RU (1) | RU2011152517A (pt) |
| TW (1) | TW201103895A (pt) |
| UY (1) | UY32716A (pt) |
| WO (1) | WO2010146395A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009539818A (ja) * | 2006-06-08 | 2009-11-19 | アストラゼネカ アクチボラグ | ベンゾイミダゾールおよび糖尿病の処置のためのその使用 |
| WO2011121350A1 (en) | 2010-04-01 | 2011-10-06 | Astrazeneca Ab | 4 -amino -7,8- dihydropyrimido [5, 4 - f] [1, 4] oxazepin- 5 ( 6h) - one based dgat1 inhibitors |
| EP2684879A1 (en) | 2012-07-09 | 2014-01-15 | Basf Se | Substituted mesoionic compounds for combating animal pests |
| JP6099753B2 (ja) | 2012-10-03 | 2017-03-22 | アドビナス セラピューティクス リミテッド | スピロ環化合物、その組成物及びその医薬応用 |
| US9079866B2 (en) * | 2013-02-04 | 2015-07-14 | Janssen Pharmaceutica Nv | Flap modulators |
| TWI644899B (zh) | 2013-02-04 | 2018-12-21 | 健生藥品公司 | Ｆｌａｐ調節劑 |
| CN103467392B (zh) * | 2013-10-09 | 2016-08-17 | 重庆工商大学 | 一种多卤代吡嗪甲酰胺衍生物及其盐类、制备方法和用途 |
| CN103880757B (zh) * | 2014-04-15 | 2016-02-24 | 上海毕得医药科技有限公司 | 一种5-羟基嘧啶-2-羧酸的合成方法 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3245989A (en) * | 1962-12-15 | 1966-04-12 | Acraf | 3-aminophenyl-5-aminoloweralkyl-1, 2, 4-oxadiazoles |
| US4983731A (en) * | 1989-03-17 | 1991-01-08 | Nebraska Department Of Economic Development | Separation and purification of sugar esters |
| US5491172A (en) * | 1993-05-14 | 1996-02-13 | Warner-Lambert Company | N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents |
| IL109431A (en) | 1993-05-14 | 2001-01-11 | Warner Lambert Co | Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds |
| GB9512697D0 (en) * | 1995-06-22 | 1995-08-23 | Zeneca Ltd | Heterocyclic compounds |
| US20030167483A1 (en) * | 1998-06-24 | 2003-09-04 | Farese Robert V. | Diacylglycerol O-acyltransferase |
| WO2000058491A1 (en) | 1999-03-25 | 2000-10-05 | The Kitasato Institute | Novel substances kf-1040t4a, kf-1040t4b, kf-1040t5a and kf-1040t5b and process for producing the same |
| TW518218B (en) | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
| GB0021670D0 (en) | 2000-09-04 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| CA2369967A1 (en) | 2001-02-12 | 2002-08-12 | Joseph Anthony Cornicelli | Methods of treating nuclear factor-kappa b mediated diseases and disorders |
| JP2002284741A (ja) | 2001-03-23 | 2002-10-03 | Kitasato Inst:The | ローズリピン誘導体 |
| DE10223273A1 (de) | 2002-05-24 | 2003-12-04 | Aventis Pharma Gmbh | Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| JP4436129B2 (ja) * | 2001-08-31 | 2010-03-24 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ジアリールシクロアルキル誘導体、その製造法及びｐｐａｒ−活性剤としてのその使用 |
| FR2840301B1 (fr) | 2002-05-29 | 2007-03-23 | Sanofi Synthelabo | Derives de phenyl-cyclohexyl-propanolamine, leur preparation et leur applicaton en therapeutique |
| DE10392752T5 (de) * | 2002-06-06 | 2005-06-02 | Kansai Technology Licensing Organization Co., Ltd. | Verfahren zur Herstellung eines multikristallinen Siliziumsubstrats für Solarzellen |
| EP1541563A4 (en) | 2002-07-10 | 2007-11-07 | Ono Pharmaceutical Co | ANTAGONIST OF CCR4 AND CORRESPONDING MEDICINAL USE |
| DE50312261D1 (de) | 2002-07-12 | 2010-02-04 | Sanofi Aventis Deutschland | Heterozyklisch substituierte benzoylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| JP4164645B2 (ja) | 2002-08-09 | 2008-10-15 | 株式会社大塚製薬工場 | Ｄｇａｔ阻害剤 |
| AU2003265659A1 (en) | 2002-08-23 | 2004-03-11 | University Of Connecticut | Novel biphenyl and biphenyl-like cannabinoids |
| US7189712B2 (en) | 2002-10-10 | 2007-03-13 | Smithkline Beecham Corporation | 1,3-Oxazole compounds for the treatment of cancer |
| AU2003293006A1 (en) | 2002-11-22 | 2004-06-18 | Japan Tobacco Inc. | Fused bicyclic nitrogen-containing heterocycles |
| SG2012000667A (en) | 2003-01-08 | 2015-03-30 | Univ Washington | Antibacterial agents |
| EP1611120A4 (en) | 2003-04-07 | 2008-04-23 | Cortical Pty Ltd | NEW METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES |
| AR044152A1 (es) | 2003-05-09 | 2005-08-24 | Bayer Corp | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad |
| EP1628666B1 (en) | 2003-05-14 | 2015-09-23 | NeuroGenetic Pharmaceuticals, Inc. | Compouds and uses thereof in modulating amyloid beta |
| EP1653969A4 (en) * | 2003-08-07 | 2006-12-20 | Japan Tobacco Inc | PYRROLO 1,2-B PYRIDAZINE DERIVATIVES |
| EP1661889A4 (en) | 2003-09-05 | 2009-08-05 | Ono Pharmaceutical Co | ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES |
| US20050143464A1 (en) | 2003-09-22 | 2005-06-30 | Use-Techno Corporation | Insulin secretion potentiator |
| BRPI0415500A (pt) | 2003-10-17 | 2007-04-10 | Incyte Corp | hidroxamatos cìclicos substituìdos como inibidores de metaloproteinases de matriz |
| GB0325192D0 (en) | 2003-10-29 | 2003-12-03 | Astrazeneca Ab | Method of use |
| US20050101660A1 (en) | 2003-11-11 | 2005-05-12 | The Skinny Drink Company | Composition for prevention and treatment of obesity, cardiovascular and coronary artery disease |
| JP2005206492A (ja) | 2004-01-21 | 2005-08-04 | Sankyo Co Ltd | スルホンアミド化合物 |
| KR20060114376A (ko) | 2004-01-30 | 2006-11-06 | 니뽄 다바코 산교 가부시키가이샤 | 식욕 감퇴 화합물 |
| EP1760071A4 (en) | 2004-06-23 | 2008-03-05 | Ono Pharmaceutical Co | COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF |
| TW200606137A (en) * | 2004-07-02 | 2006-02-16 | Sankyo Co | Urea derivatives |
| WO2006019020A1 (ja) | 2004-08-16 | 2006-02-23 | Sankyo Company, Limited | 置換されたウレア化合物 |
| MX2007004217A (es) | 2004-10-15 | 2007-06-11 | Bayer Pharmaceuticals Corp | Preparacion y uso de derivados de acido bifenil-4-il-carbonilamino para el tratamiento de obesidad. |
| WO2006054370A1 (en) | 2004-11-16 | 2006-05-26 | Use-Techno Corporation | Gluconeogenesis inhibiting agent |
| MX2007007101A (es) * | 2004-12-14 | 2007-08-21 | Astrazeneca Ab | Derivados de oxadiazol como inhibidores de acil coa:diacilglicerol aciltransferasa. |
| WO2006082952A1 (ja) | 2005-02-01 | 2006-08-10 | Takeda Pharmaceutical Company Limited | アミド化合物 |
| CN101115711A (zh) | 2005-02-07 | 2008-01-30 | 霍夫曼-拉罗奇有限公司 | 二酰基甘油酰基转移酶(dgat)的抑制剂 |
| CN101198333A (zh) | 2005-04-19 | 2008-06-11 | 拜尔药品公司 | 芳烷基酸衍生物及其用途 |
| CN101171231A (zh) | 2005-05-10 | 2008-04-30 | 霍夫曼-拉罗奇有限公司 | 二酰基甘油酰基转移酶抑制剂 |
| EP1893592A1 (en) * | 2005-06-11 | 2008-03-05 | AstraZeneca AB | Oxadiazole derivatives as dgat inhibitors |
| WO2007007588A1 (ja) | 2005-07-08 | 2007-01-18 | Ono Pharmaceutical Co., Ltd. | 平面性を有する環状基を母核とする化合物 |
| JP2009505962A (ja) | 2005-07-29 | 2009-02-12 | バイエル・ヘルスケア・エルエルシー | 肥満を治療するためのビフェニルアミノ酸誘導体の製造および使用 |
| JP2007131584A (ja) | 2005-11-11 | 2007-05-31 | Sankyo Co Ltd | 新規ベンゾオキサゾール誘導体 |
| EP1963313B1 (en) * | 2005-11-28 | 2012-11-14 | Madrigal Pharmaceuticals, Inc. | Inhibitors of diacylglycerol acyltransferase (dgat) |
| JP2007191471A (ja) | 2005-12-21 | 2007-08-02 | Sankyo Co Ltd | ウレア誘導体を含有する医薬 |
| AR058562A1 (es) * | 2005-12-22 | 2008-02-13 | Astrazeneca Ab | Derivados de pirimido [4,5 b] (1,4) oxazinas , procedimientos de obtencion y su uso como inhibidores de acetil coa y dgat 1 |
| WO2007074753A1 (ja) | 2005-12-27 | 2007-07-05 | Daiichi Sankyo Company, Limited | 置換されたウレア誘導体を含有する医薬 |
| WO2007126957A2 (en) * | 2006-03-31 | 2007-11-08 | Novartis Ag | New compounds |
| CN101541747B (zh) | 2006-04-21 | 2012-11-14 | 伊莱利利公司 | 作为11-β-羟基甾族化合物脱氢酶1的抑制剂的联苯基酰胺内酰胺衍生物 |
| US20080015227A1 (en) | 2006-05-19 | 2008-01-17 | Kym Philip R | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme |
| US20080064717A1 (en) | 2006-05-19 | 2008-03-13 | Rajesh Iyengar | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme |
| BRPI0712802A2 (pt) | 2006-05-30 | 2012-10-23 | Astrazeneca Ab | composto, métodos para produzir uma inibição da atividade de dgat1, e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para preparar um composto |
| CA2651663A1 (en) | 2006-05-30 | 2007-12-06 | Astrazeneca Ab | Chemical compounds |
| CN101460469A (zh) * | 2006-06-06 | 2009-06-17 | 阿斯利康(瑞典)有限公司 | 化合物 |
| JP2009539818A (ja) | 2006-06-08 | 2009-11-19 | アストラゼネカ アクチボラグ | ベンゾイミダゾールおよび糖尿病の処置のためのその使用 |
| GB0611507D0 (en) | 2006-06-10 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
| GB0611506D0 (en) * | 2006-06-10 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
| GB0611552D0 (en) | 2006-06-12 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
| US20120065196A1 (en) | 2006-07-21 | 2012-03-15 | Shuji Kitamura | Amide compounds |
| JP2009544616A (ja) | 2006-07-21 | 2009-12-17 | 武田薬品工業株式会社 | アミド化合物 |
| US7569590B2 (en) * | 2006-09-19 | 2009-08-04 | Bristol-Myers Squibb Company | Use of thianecarboxamides as dgat inhibitors |
| KR100795462B1 (ko) | 2006-09-27 | 2008-01-16 | 한국생명공학연구원 | 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물 |
| KR100811100B1 (ko) | 2006-09-27 | 2008-03-06 | 한국생명공학연구원 | 벤즈아졸 유도체를 유효성분으로 함유하는 대사성 질환예방 및 치료용 약학적 조성물 |
| BRPI0717845A2 (pt) | 2006-10-04 | 2015-06-16 | Hoffmann La Roche | Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos |
| AR063311A1 (es) | 2006-10-18 | 2009-01-21 | Novartis Ag | Compuestos organicos |
| WO2008046216A1 (en) | 2006-10-18 | 2008-04-24 | Methylgene, Inc. | Kinase inhibitors and uses thereof |
| WO2008058402A1 (en) | 2006-11-17 | 2008-05-22 | Queen's University At Kingston | Compounds and methods for treating protein folding disorders |
| BRPI0719352A2 (pt) | 2006-11-29 | 2017-10-24 | Abbott Lab | inibidores de enzima diacilglicerol o-aciltransferase tipo 1 |
| JP2010512410A (ja) | 2006-12-11 | 2010-04-22 | ノバルティス アーゲー | 心筋虚血を予防または処置するための方法 |
| CA2685529A1 (en) * | 2007-04-30 | 2008-11-06 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
| US8058299B2 (en) * | 2007-05-22 | 2011-11-15 | Via Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| JP2010536839A (ja) | 2007-08-17 | 2010-12-02 | アストラゼネカ アクチボラグ | 化合物９７９ |
| CN101932562B (zh) * | 2007-12-20 | 2013-06-12 | 阿斯利康(瑞典)有限公司 | 作为dgat1抑制剂190的氨基甲酰基化合物 |
| JP2010132590A (ja) | 2008-12-03 | 2010-06-17 | Astellas Pharma Inc | オキサジアゾール化合物 |
| MX2011006672A (es) * | 2008-12-19 | 2011-07-20 | Astrazeneca Ab | Derivados de 1,3,4-oxadiazol y sus usos para tratar diabetes. |
-
2010
- 2010-06-17 WO PCT/GB2010/051003 patent/WO2010146395A1/en not_active Ceased
- 2010-06-17 EP EP10725494A patent/EP2443096A1/en not_active Withdrawn
- 2010-06-17 JP JP2012515565A patent/JP2012530122A/ja active Pending
- 2010-06-17 BR BRPI1016109A patent/BRPI1016109A2/pt not_active Application Discontinuation
- 2010-06-17 TW TW099119725A patent/TW201103895A/zh unknown
- 2010-06-17 KR KR1020127001363A patent/KR20120037939A/ko not_active Withdrawn
- 2010-06-17 CA CA2764013A patent/CA2764013A1/en not_active Abandoned
- 2010-06-17 RU RU2011152517/04A patent/RU2011152517A/ru unknown
- 2010-06-17 CN CN201080036012XA patent/CN102498103A/zh active Pending
- 2010-06-17 AU AU2010261499A patent/AU2010261499A1/en not_active Abandoned
- 2010-06-17 MX MX2011014018A patent/MX2011014018A/es not_active Application Discontinuation
- 2010-06-17 UY UY0001032716A patent/UY32716A/es unknown
- 2010-06-18 AR ARP100102161A patent/AR077140A1/es unknown
- 2010-06-18 US US12/818,187 patent/US8188092B2/en not_active Expired - Fee Related
-
2012
- 2012-04-25 US US13/455,275 patent/US20120289520A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US8188092B2 (en) | 2012-05-29 |
| US20120289520A1 (en) | 2012-11-15 |
| CN102498103A (zh) | 2012-06-13 |
| JP2012530122A (ja) | 2012-11-29 |
| AR077140A1 (es) | 2011-08-03 |
| CA2764013A1 (en) | 2010-12-23 |
| RU2011152517A (ru) | 2013-07-27 |
| AU2010261499A1 (en) | 2012-01-12 |
| UY32716A (es) | 2011-01-31 |
| EP2443096A1 (en) | 2012-04-25 |
| TW201103895A (en) | 2011-02-01 |
| MX2011014018A (es) | 2012-02-22 |
| KR20120037939A (ko) | 2012-04-20 |
| US20100324068A1 (en) | 2010-12-23 |
| WO2010146395A1 (en) | 2010-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0818533A2 (pt) | composto, composição farmacêutica, e, processo para a preparação de um composto | |
| BRPI0909691A8 (pt) | composto, método para preparar um composto, e, composição farmacêutica | |
| BRPI1006162A2 (pt) | "composto,processo para preparar um composto,formulação farmacêutica,e uso de um composto". | |
| BRPI0910734A2 (pt) | composto, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo. | |
| BRPI0905717A2 (pt) | Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica | |
| BRPI0811712A2 (pt) | "composto, processo de preparação de um composto e composição farmacéutica". | |
| BR112013008008A2 (pt) | composto, composição farmacêutica e processo para preparar um composto | |
| BRPI0821676A2 (pt) | Composto, composição farmacêutica, e, processo para a preparação dos compostos. | |
| BRPI1007161A2 (pt) | composição farmacêutica oral, e processo para preparar uma composição | |
| BRPI0814821A2 (pt) | Composto, composição farmacêutica, e, processo para preparar um composto | |
| BRPI0816331A2 (pt) | Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto. | |
| BRPI1010128A2 (pt) | "processo para a fabricação do 2,3,3,3 - tetrafluropropeno" | |
| BRPI1011888A2 (pt) | processo para preparar um composto, e, composição. | |
| BRPI0905847A2 (pt) | "composição farmacêutica injetável e processo para preparar a composição" | |
| BR112012016201A2 (pt) | ''composto, processo para a preparação de um composto, composição farmacêutica e uso de um composto'' | |
| BRPI0815784A2 (pt) | Processo para a preparação de 1,2-propanodiol | |
| BRPI1010933A2 (pt) | processo para a preparação de um pó, e, composto | |
| BRPI1014547A2 (pt) | composto, e, processo para preparar um composto. | |
| BRPI0911897A2 (pt) | Processo para a preparação de compostos, e, composto | |
| BRPI1014691A2 (pt) | Composto, e, processo para a preparação de um composto. | |
| BRPI0922714A2 (pt) | composto, processo para preparar um compsoto, medicamento, uso de um composto, e, composição farmacêutica | |
| BRPI1016109A2 (pt) | "composto, composição farmacêutica, e, processo para preparar um composto" | |
| BRPI0815971A2 (pt) | Processo para a preparação de 1,2-propanodiol | |
| BRPI0813772A2 (pt) | Composto, processo para a preparação de um composto, e, conjugado | |
| BRPI1007654A2 (pt) | composto, processo para a obtenção de um composto de fórmula geral e composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |